TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02159326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas,BAY63-2521)
Description: multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
Study: NCT02975310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: ESS will be performed under general anesthesia in the operating room

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local and topical anesthesia
Description: EPIC will be performed under topical and local anesthesia in a clinic setting
Study: NCT00881842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study: NCT01843569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: In Vitro maturation
Study: NCT04206098

Intervention type: OTHER
Intervention: Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)
Description: Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
Study: NCT01653834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphocyte harvesting & reinfusion
Description: Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
Study: NCT01124734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
Study: NCT04460313

Intervention type: OTHER
Group type: OTHER
Intervention: nasopharyngeal sample
Description: Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.

Intervention type: OTHER
Group type: OTHER
Intervention: nasopharyngeal sample
Description: Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.

Intervention type: OTHER
Group type: OTHER
Intervention: Stools collection or anorectal swab samples
Description: For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
Study: NCT02034903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedings warmed with commercial warmer
Study: NCT02269280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) Days 1 - 3
Description: Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
Study: NCT02964286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Electric vibrating massager,SAMPO®
Description: The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
Study: NCT01419704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoetic Stem Cell Infusion
Description: Enriched Hematopoetic Stem Cell Infusion
Study: NCT00747617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin
Description: Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin
Description: Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
Study: NCT03431324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking about Mating Opportunities
Description: Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Mating-EFT Intervention
Description: This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate.
Study: NCT00683475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
Study: NCT02625324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Evo Thoracic Stent Graft System
Description: Procedure: thoracic endovascular aneurysm repair (TEVAR)
Study: NCT03148431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3002815
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01865435

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cord blood sample
Study: NCT02130479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management-Family Engagement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT00352755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical debulking with peritonectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Study: NCT05294822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus
Description: Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
Study: NCT02144558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: penile vibratory stimulation (PVS) or masturbation
Description: penile vibratory stimulation (PVS) or masturbation
Study: NCT02269280

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (BSC)
Description: Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) Days 1 - 5
Description: Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
Study: NCT01528306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each
Study: NCT04603625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postural management
Description: postural management in sitting position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural management
Description: postural management in sitting position
Study: NCT02471755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eelectro-acupuncture
Description: The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Eelectro-acupuncture
Description: Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
Study: NCT03516435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical stimulation
Description: Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal electrical stimulation
Description: Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
Study: NCT00552942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic gastric bypass plus omentectomy
Study: NCT01965184

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Study: NCT03954197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hCG
Description: a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GnRH a
Description: a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GnRH a
Description: a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
Study: NCT02543710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker (ER/PR) guided lymphadenectomy
Description: Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
Description: A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression.
Study: NCT01492985

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos of GTU-multiHIV B and LIPO-5 vaccines
Description: Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-multHIV B vaccine and LIPO-5 vaccine
Description: Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
Study: NCT01090271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training
Description: The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
Study: NCT03005067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbomer 980 (1146A)
Description: Test product containing carbomer 980 gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference product containing vehicle without carbomer 980 gel
Study: NCT01956448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
Study: NCT01509482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples to test for primary and secondary outcome measures
Study: NCT03233633

Intervention type: DRUG
Group type: OTHER
Intervention: Medical Marijuana
Description: oral capsule, high ratio CBD:THC
Study: NCT01509482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: IR Cholesterol HDL LDL Fasting Glucose Triglycerides
Study: NCT04062149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single leg stance treatment
Description: SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy
Description: Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
Study: NCT02508038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCRαβ+/CD19+ depleted Haploidentical HSCT
Description: Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
Study: NCT01996059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Jejunal Interposition
Description: First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
Study: NCT02794571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
Study: NCT04548830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy
Description: After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
Study: NCT02794571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
Study: NCT01298323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient outreach
Description: Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Treatment 300mg vandetanib opel label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: Treatment 300mg vandetanib opel label.